MedTrace Logo

Effect of, OAT3, on the Renal Secretion of Cefotaxime

NCT00187655 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-10-29

Study results available
· View outcomes & findings →

Summary

In the proposed study, we plan to use a genotype to phenotype strategy to study the role of the organic anion transporter, OAT3, in drug response. More specifically we will examine the contribution of OAT3 to the renal clearance of anionic drugs such as cefotaxime by studying individuals with a non-functional (or poorly-functional) variant of OAT3.

Conditions

  • Focus Groups

Interventions

DRUG

Cefotaxime

Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.

Sponsors & Collaborators

Principal Investigators

  • Kathleen Giacomini, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2011-12-31
Completion
2013-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187655 on ClinicalTrials.gov